Market capitalization | €845.49m |
Enterprise Value | €825.32m |
P/E (TTM) P/E ratio | 25.28 |
EV/FCF (TTM) EV/FCF | 36.42 |
EV/Sales (TTM) EV/Sales | 3.02 |
P/S ratio (TTM) P/S ratio | 3.09 |
P/B ratio (TTM) P/B ratio | 3.42 |
Dividend yield | 0.12% |
Last dividend (FY23) | €0.05 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Eckert & Ziegler Strahlen- und Medizintechnik:
1 Analyst has issued a forecast Eckert & Ziegler Strahlen- und Medizintechnik:
Jun '24 |
+/-
%
|
||
Revenue | 274 274 |
17%
17%
|
|
Gross Profit | 132 132 |
21%
21%
|
|
EBITDA | 77 77 |
30%
30%
|
EBIT (Operating Income) EBIT | 64 64 |
33%
33%
|
Net Profit | 33 33 |
35%
35%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. It operates through the following segments: Radiation Therapy, Isotope Products, and Radiopharma. The Radiation Therapy segment includes the production and distribution of medical products for the treatment of cancer using brachytherapy. The Isotope Products segment manufactures and distributes sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment is specialized in the field of molecular imaging and nuclear medicine, supplying different radiopharmaceuticals, radiochemicals and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. The company was founded by Andreas Eckert in 1997 and is headquartered in Berlin, Germany.
Head office | Germany |
CEO | Harald Hasselmann |
Employees | 1,075 |
Founded | 1997 |
Website | www.ezag.de |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.